Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease

Benjamin, Jane L, Hedin, Charlotte R H, Koutsoumpas, Andreas, Ng, Siew C, McCarthy, Neil E, Hart, Ailsa L, Kamm, Michael A, Sanderson, Jeremy D, Knight, Stella C, Forbes, Alastair ORCID: https://orcid.org/0000-0001-7416-9843, Stagg, Andrew J, Whelan, Kevin and Lindsay, James O (2011) Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut, 60 (7). pp. 923-9. ISSN 0017-5749

Full text not available from this repository. (Request a copy)

Abstract

The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.

Item Type:	Article
Uncontrolled Keywords:	adult,bifidobacterium,crohn disease,dendritic cells,double-blind method,feces,female,humans,immunity, mucosal,intestinal mucosa,male,medication adherence,middle aged,oligosaccharides,prebiotics,rectum,treatment outcome
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine
Depositing User:	Pure Connector
Date Deposited:	06 Aug 2014 10:38
Last Modified:	20 Oct 2022 19:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/49785
DOI:	10.1136/gut.2010.232025

Actions (login required)

View Item